You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

385 Results
The Radiation Treatment Program ensures timely access to safe, evidence-based, high-quality radiation treatment. To improve patient experience and...
Guidelines and Advice
Status: Current
Version: 1
Nov 2024
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Myeloproliferative Neoplasms (MPNs)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ruxolitinib - For patients with intermediate to high risk symptomatic myelofibrosis, or patients with symptomatic splenomegaly, according to specific criteria
Exceptional Access Program
    ruxolitinib - For the treatment of patients with polycythemia vera according to criteria.
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ruxolitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Recognizing the challenge and opportunity of take-home cancer medications, Cancer Care Ontario hosted a policy planning and consultation session in...
Reconnaissant le défi et la possibilité des médicaments contre le cancer à prendre à la maison, Action Cancer Ontario a organisé une séance de...
Document
New
Mar 2025
Guidelines and Advice
Status: Current
ID: PET 2024-1
Updated
Mar 2025
Document
New
Apr 2025

Pages